cardioКардиологияKardiologiia0022-90402412-5660Kardiomag10.18087/cardio.2020.8.n1244cardio-1244Research ArticleОБЗОРЫREVIEWSПрямой пероральный антикоагулянт эдоксабан у больных с неклапанной фибрилляцией предсердий: результаты прямого сравнения с варфариномDirect Oral Anticoagulant Edoxaban in Patients with Non-Valvular Atrial Fibrillation: Results of Direct Comparison with Warfarinhttps://orcid.org/0000-0003-2816-1183ЯвеловИ. С.YavelovI. S.

д.м.н., ведущий научный сот рудник отдела клинической кардиологии и молекулярной генетики ФГБУ "НМИЦ профилактической медицины" Минздрава России

Doctor of Medical Sciences, Leading Researcher of the Department of Clinical Cardiology and Molecular Genetics of the Federal State Budgetary Institution "National Medical Research Center of Preventive Medicine" of the Ministry of Health of Russia

IYavelov@gnicpm.ruФГБУ «Национальный медицинский исследовательский центр терапии и профилактической медицины» Минздрава России, МоскваРоссия"National Medical Research Center for Therapy and Preventive Medicine" of the Ministry of Health of Russia, MoscowRussian Federation202017092020608124129Copyright © Kardiomag, 20202020KardiomagKardiomaghttps://cardio.elpub.ru/jour/about/submissions#copyrightNoticehttps://cardio.elpub.ru/jour/article/view/1244

В обзоре анализируются результаты крупного проспективного рандомизированного двойного слепого плацебо-контролируемого клинического исследования ENGAGE AF-TIMI 48 по сопоставлению эффективности и безопасности антагониста витамина К варфарина и перорального ингибитора активированного Х фактора свертывания крови эдоксабана. Рассматриваются практически важные особенности использования эдоксабана у больных с неклапанной фибрилляцией предсердий.

This review analyzes results of a large prospective, randomized, double-blind, placebo-controlled clinical study ENGAGE AF-TIMI 48 that compared efficacy and safety of warfarin, a vitamin K antagonist, and edoxaban, an oral inhibitor of activated coagulation factor X. The review addresses important practical aspects of using edoxaban in patients with nonvalvular atrial fibrillation.

Фибрилляция предсердийнеклапанная фибрилляция предсердийварфаринэдоксабанAtrial fibrillationnonvalvular atrial fibrillationwarfarinedoxabanReferencesKirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;37(38):2893–962. DOI: 10.1093/eurheartj/ehw210Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;37(38):2893–962. DOI: 10.1093/eurheartj/ehw210Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al. Edoxaban versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine. 2013;369(22):2093–104. DOI: 10.1056/NEJMoa1310907Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al. Edoxaban versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine. 2013;369(22):2093–104. DOI: 10.1056/NEJMoa1310907Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal. 2018;39(16):1330– 93. DOI: 10.1093/eurheartj/ehy136Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal. 2018;39(16):1330– 93. DOI: 10.1093/eurheartj/ehy136Bergmark BA, Kamphuisen PW, Wiviott SD, Ruff CT, Antman EM, Nordio F et al. Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial. Circulation. 2019;140(22):1792– 801. DOI: 10.1161/CIRCULATIONAHA.119.041346Bergmark BA, Kamphuisen PW, Wiviott SD, Ruff CT, Antman EM, Nordio F et al. Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial. Circulation. 2019;140(22):1792– 801. DOI: 10.1161/CIRCULATIONAHA.119.041346Bohula EA, Giugliano RP, Ruff CT, Kuder JF, Murphy SA, Antman EM et al. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation. 2016;134(1):24–36. DOI: 10.1161/CIRCULATIONAHA.116.022361Bohula EA, Giugliano RP, Ruff CT, Kuder JF, Murphy SA, Antman EM et al. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation. 2016;134(1):24–36. DOI: 10.1161/CIRCULATIONAHA.116.022361Nicolau AM, Corbalan R, Nicolau JC, Ruff CT, Zierhut W, Kerschnitzki M et al. Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial. European Heart Journal - Cardiovascular Pharmacotherapy. 2020;6(3):167–75. DOI: 10.1093/ehjcvp/pvz061Nicolau AM, Corbalan R, Nicolau JC, Ruff CT, Zierhut W, Kerschnitzki M et al. Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial. European Heart Journal - Cardiovascular Pharmacotherapy. 2020;6(3):167–75. DOI: 10.1093/ehjcvp/pvz061Steffel J, Giugliano RP, Braunwald E, Murphy SA, Mercuri M, Choi Y et al. Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling. Journal of the American College of Cardiology. 2016;68(11):1169–78. DOI: 10.1016/j.jacc.2016.06.034Steffel J, Giugliano RP, Braunwald E, Murphy SA, Mercuri M, Choi Y et al. Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling. Journal of the American College of Cardiology. 2016;68(11):1169–78. DOI: 10.1016/j.jacc.2016.06.034De Caterina R, Renda G, Carnicelli AP, Nordio F, Trevisan M, Mercuri MF et al. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial. Journal of the American College of Cardiology. 2017;69(11):1372–82. DOI: 10.1016/j.jacc.2016.12.031De Caterina R, Renda G, Carnicelli AP, Nordio F, Trevisan M, Mercuri MF et al. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial. Journal of the American College of Cardiology. 2017;69(11):1372–82. DOI: 10.1016/j.jacc.2016.12.031Carnicelli AP, De Caterina R, Halperin JL, Renda G, Ruff CT, Trevisan M et al. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. Circulation. 2017;135(13):1273–5. DOI: 10.1161/CIRCULATIONAHA.116.026714Carnicelli AP, De Caterina R, Halperin JL, Renda G, Ruff CT, Trevisan M et al. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. Circulation. 2017;135(13):1273–5. DOI: 10.1161/CIRCULATIONAHA.116.026714Qamar A, Antman EM, Ruff CT, Nordio F, Murphy SA, Grip LT et al. Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease. Journal of the American College of Cardiology. 2019;74(2):179–89. DOI: 10.1016/j.jacc.2019.04.061Qamar A, Antman EM, Ruff CT, Nordio F, Murphy SA, Grip LT et al. Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease. Journal of the American College of Cardiology. 2019;74(2):179–89. DOI: 10.1016/j.jacc.2019.04.061Mega JL, Walker JR, Ruff CT, Vandell AG, Nordio F, Deenadayalu N et al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. The Lancet. 2015;385(9984):2280–7. DOI: 10.1016/S0140-6736(14)61994-2Mega JL, Walker JR, Ruff CT, Vandell AG, Nordio F, Deenadayalu N et al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. The Lancet. 2015;385(9984):2280–7. DOI: 10.1016/S0140-6736(14)61994-2

The authors declare that there are no conflicts of interest present.